Complete Conditioned Medium
Contains soluble cell-derived factors, extracellular vesicles and residual components from the original culture system.
CELLMEX Scientific Library
Exosome-Depleted Conditioned Media
Exosome-depleted conditioned medium is a processed cell-culture preparation in which extracellular vesicles are intentionally reduced while soluble cell-derived proteins, cytokines, chemokines, growth factors, metabolites and other non-vesicular components are retained.
Scientific Definition
What exactly is exosome-depleted conditioned medium?
Cells maintained in culture release biological material into the surrounding culture medium. After a defined conditioning period, this medium is collected and described as conditioned medium.
Conditioned medium may contain soluble proteins, cytokines, chemokines, growth factors, metabolites, extracellular-matrix-associated components and several populations of extracellular vesicles.
Exosome-depleted conditioned medium is produced by processing conditioned medium to reduce its small extracellular-vesicle or exosome-associated fraction while retaining much of the soluble, non-vesicular secretome.
EV-Enriched Fraction
Contains an increased relative concentration of extracellular vesicles recovered from conditioned medium.
EV-Depleted Fraction
The remaining conditioned medium after a defined process has reduced the extracellular-vesicle fraction.
Soluble Secretome Biology
Biological signalling without the principal EV fraction
The purpose of EV depletion is often to study or develop the soluble component of the cellular secretome separately from extracellular-vesicle activity.
Soluble Cytokines
Cytokines participate in immune communication, inflammatory signalling and regulation of cellular responses.
Chemokines
Chemokines can influence cellular migration, recruitment and interaction within tissue environments.
Growth Factors
Growth factors may influence proliferation, survival, vascular signalling, matrix production and repair-associated pathways.
Enzymes and Regulatory Proteins
Soluble enzymes and proteins may influence extracellular-matrix turnover, inflammation and local tissue signalling.
Metabolites and Lipid Mediators
Secreted metabolites and non-vesicular lipid mediators may contribute to cellular communication and metabolic regulation.
Residual Culture Components
The preparation may retain proteins, supplements or other components from the culture medium unless they are specifically removed.
Laboratory Production
How the preparation is produced
The preparation is not differentiated. It is collected, clarified, fractionated and analytically evaluated.
Source-Cell Qualification
Define the cell type, tissue source, donor, passage number, identity and culture history.
Controlled Cellular Expansion
Maintain the cells under documented media, supplement, oxygen, density and environmental conditions.
Conditioning Phase
Place the cells in a defined collection medium for a controlled period during which soluble and vesicular factors accumulate.
Medium Collection
Collect the conditioned medium using a documented procedure designed to preserve traceability and reduce contamination.
Clarification
Remove intact cells, cellular debris and larger particulate material through centrifugation, filtration or related processing.
Extracellular-Vesicle Depletion
Reduce the vesicle fraction using ultracentrifugation, ultrafiltration, size-exclusion, affinity-based processing or a validated combination of methods.
Concentration and Formulation
Concentrate the soluble fraction where required and prepare the intended carrier, concentration and container.
Analytical Verification
Compare conditioned medium before and after depletion to document particle reduction, composition and retained biological activity.
Storage and Stability
Establish storage temperature, holding time, freeze–thaw limitations and transport conditions.
Product Composition
What may remain after EV depletion?
Composition depends on the source cells, culture conditions, collection system, depletion method and subsequent processing.
Soluble Proteins
Cell-derived proteins may remain freely dissolved in the preparation.
Cytokines and Chemokines
Immune and inflammatory signalling molecules may remain after vesicle depletion.
Growth and Trophic Factors
Selected factors associated with cell survival, vascular signalling and tissue-support pathways may be retained.
Enzymes and Matrix Factors
Soluble matrix-associated and regulatory proteins may remain within the preparation.
Metabolites
Cellular metabolic products may contribute to the composition and biological response.
Residual Extracellular Vesicles
A measurable residual vesicle population may remain depending on depletion efficiency.
Media-Derived Components
Basal media, supplements and carrier proteins may remain unless removed through downstream processing.
Process-Related Residuals
Filters, membranes, reagents or concentration processes may introduce or retain process-related materials.
Batch-Specific Profile
Each batch may differ according to cell number, cellular condition, conditioning period and processing recovery.
Potential Uses and Indications
Current use is primarily experimental
Exosome-depleted conditioned medium is most commonly used as a comparative research fraction, a soluble secretome platform or a starting material for further product development.
Mechanism Comparison
Researchers compare complete conditioned medium, EV-enriched fractions and EV-depleted fractions to determine which biological effects are vesicle-dependent.
Immunological Signalling
Soluble factors may be studied for their influence on macrophages, lymphocytes, dendritic cells and inflammatory pathways.
Wound and Skin Biology
Laboratory studies may examine fibroblast behaviour, epithelial repair, angiogenic signalling and matrix production.
Musculoskeletal Research
Soluble secretome fractions may be evaluated in cartilage, tendon, muscle, bone and inflammatory joint models.
Neurological Research
Studies may investigate trophic, anti-inflammatory and cytoprotective signalling in neural-cell or injury models.
Organ-Injury Models
Soluble factors may be studied in pulmonary, renal, hepatic and cardiovascular injury models.
Defined Protein Formulations
The soluble fraction may support identification and development of selected proteins or factor combinations.
EV-Depletion Controls
EV-depleted media may serve as an experimental control when evaluating isolated extracellular vesicles.
Cell-Free Biologic Development
Research may examine whether defined soluble secretome fractions can be standardised as cell-free biological preparations.
Current Medical Use
Not an established routine treatment
Exosome-depleted conditioned medium is not broadly established as a standard medical treatment for a defined disease.
Its present role is principally within laboratory research, mechanism-of-action studies, preclinical development and the design of more defined cell-free biological products.
Commercial availability, topical use or use by a treatment facility does not independently demonstrate clinical efficacy, product standardisation or regulatory authorisation.
Individual Protocol Development
Patient-specific preparation rather than mass marketing
A patient-linked preparation may be developed only where scientifically justified and legally permitted. Individual production does not itself establish safety or effectiveness.
Physician Review
The diagnosis, conventional treatment options, scientific rationale and patient-specific risks are evaluated.
Protocol Definition
The source cells, conditioning process, depletion method, testing and intended research objective are documented.
Source-Cell Assignment
The preparation may be linked to autologous cells or to a defined qualified donor-cell bank, depending on the protocol.
Batch Manufacturing
Collection, EV depletion, concentration, formulation, testing and deviations are documented for the individual batch.
Clinical Governance
Any proposed use requires medical review, informed consent, applicable authorisation, monitoring and follow-up.
Not inherently personalised medicine
EV-depleted conditioned medium is not automatically patient-specific merely because it is produced in a laboratory.
Personalisation requires a documented connection between the patient, source material, manufacturing protocol, clinical rationale and final preparation.
Characterisation and Quality Control
Depletion and composition must be demonstrated
A preparation should not be labelled exosome-depleted solely because it has undergone centrifugation or filtration.
Source-Cell Identity
Document cell type, tissue source, donor, phenotype, passage and culture history.
Pre-Depletion Particle Profile
Characterise the particle concentration and size distribution of the original conditioned medium.
Post-Depletion Particle Profile
Measure the residual particle population after depletion using an appropriate analytical method.
Depletion Efficiency
Calculate and document the reduction achieved by the selected process.
Soluble Protein Profile
Evaluate total protein and selected cytokines, chemokines or growth factors where relevant.
Media and Process Residuals
Assess residual supplements, proteins, reagents and processing materials.
Microbiological Quality
Review sterility-related testing, mycoplasma and endotoxin where applicable.
Functional Activity
Use a fit-for-purpose assay linked to the proposed soluble-factor mechanism.
Stability
Establish how storage, transport, holding time and freeze–thaw exposure affect composition and activity.
Clinical and scientific qualification
Exosome-depleted conditioned medium is not the same as purified exosomes, small extracellular vesicles, complete secretome or unprocessed conditioned medium.
The term “exosome-depleted” should be supported by analytical evidence. Commercially described “exosome-free” materials should not be presumed to contain no extracellular vesicles.
Biological activity observed in cell culture or animal studies does not independently establish safety or effectiveness in human patients.
Potential applications in orthopaedics, neurology, dermatology, autoimmune disease, organ injury or other fields remain investigational unless supported by product-specific clinical evidence and applicable regulatory authorisation.
Patient-specific production does not remove the need for manufacturing controls, ethical review, regulatory compliance, informed consent and clinical monitoring.
The CELLMEX Approach
Fraction-specific development and responsible translation
Define the Source Cells
Establish cell identity, tissue origin, donor information, passage and culture history.
Control Conditioning
Standardise media, cell density, conditioning duration, oxygen and environmental conditions.
Verify EV Depletion
Compare pre-depletion and post-depletion particle measurements rather than relying only on the processing method.
Characterise Soluble Factors
Evaluate relevant proteins, cytokines, growth factors, metabolites and process-related components.
Establish Functional Activity
Use mechanism-relevant assays to determine whether the remaining soluble fraction demonstrates the intended biological effect.
Maintain Clinical Separation
Clearly distinguish experimental development from established medical treatment and avoid broad disease claims.
Selected Scientific References
EV depletion, conditioned media and secretome research
Welsh JA, et al. Minimal information for studies of extracellular vesicles: MISEV2023.
Journal of Extracellular Vesicles. 2024;13:e12404.
View publicationPachler K, et al. A Good Manufacturing Practice-grade standard protocol for exclusively human mesenchymal stromal cell-derived extracellular vesicles.
Cytotherapy. 2017;19(4):458–472.
View publicationFerreira JR, et al. Mesenchymal Stromal Cell Secretome: Influencing Therapeutic Potential by Cellular Pre-conditioning.
Frontiers in Immunology. 2018;9:2837.
View publicationKumar P, et al. The mesenchymal stem cell secretome: A new paradigm towards cell-free therapeutic mode in regenerative medicine.
Cytokine & Growth Factor Reviews. 2019;46:1–9.
View publicationBiancone L, et al. Therapeutic potential of mesenchymal stem cell-derived microvesicles.
Research comparing extracellular-vesicle and EV-depleted conditioned-media activity.
View related publicationU.S. Food and Drug Administration. Consumer alert concerning regenerative-medicine products, including exosome products.
Regulatory and patient-safety information.
View FDA information
Scientific Information
Request information concerning CELLMEX cell-free research
Physicians, researchers and institutions may request information concerning conditioned media, extracellular-vesicle depletion, soluble secretome characterisation, functional assays and scientific collaboration.